Human Dopaminergic Progenitor Cells
Early-onset Parkinson's Disease
iRegene Therapeutics Co., Ltd.Cell therapyPhase 1Active
CC
43/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 28/ 100
- Competitive Position
- 95/ 100
Competitive context
1 Active assets in the Early-onset Parkinson's Disease cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
aav2-haadc Krzysztof Bankiewicz | Phase 1 | CC |
Same molecule, other indications
Human Dopaminergic Progenitor Cells is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →